Search

Your search keyword '"Dharmadhikari, Bhushan"' showing total 35 results

Search Constraints

Start Over You searched for: Author "Dharmadhikari, Bhushan" Remove constraint Author: "Dharmadhikari, Bhushan"
35 results on '"Dharmadhikari, Bhushan"'

Search Results

1. Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies

2. Graphene Quantum Dot Oxidation Governs Noncovalent Biopolymer Adsorption.

3. Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit

8. 623 Trial in progress: A phase 1 first-in-human study of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies

10. Rationally targeted anti-VISTA antibody that blockades the C-C’ loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner

13. Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit

15. Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies

16. Impact of glucocorticoids on the incidence of lupus-related major organ damage:A systematic literature review and meta-regression analysis of longitudinal observational studies

20. Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma (NPC).

21. Deletion of CD137 Ligand Exacerbates Renal and Cutaneous but Alleviates Cerebral Manifestations in Lupus

29. CD137L dendritic cells induce potent response against cancer-associated viruses and polarize human CD8+ T cells to Tc1 phenotype.

30. A phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, in advanced solid tumors.

33. CD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses.

34. Advances in Structural Modifications and Properties of Graphene Quantum Dots for Biomedical Applications.

35. Graphene Quantum Dots: Synthesis and Applications.

Catalog

Books, media, physical & digital resources